Skip to main content

Table 3 Adherence to NICE and local VTE pharmacological prophylaxis guidelines (urology department)

From: Thromboprophylaxis prescribing among junior doctors: the impact of educational interventions

Parameter Measured

(N) Number of patients included

Pre-proforma (N = 25)

Post- proforma (N = 12)

Post- changeover of doctors (N = 28)

Post-teaching (N = 19)

Indication(s) for pharmacological VTE prophylaxis present, % (number)

y = 92.0(23)

n = 8.0(2)

y = 66.7(8)

n = 33.3(4)

y = 96.4(27)

n = 3.6(1)

y = 100(19)

Contraindication(s) for pharmacological VTE prophylaxis present, % (number)

y = 32.0(8)

n = 64.0(16)

u/n = 4.0(1)

y = 41.7(5)

n = 58.3(7)

y = 17.9(5)

n = 78.6(22)

u/n = 3.6(1)

y = 42.1(8)

n = 57.9(11)

Documentation of risk assessment, % (number)

y = 8.0 %(2)

n = 88.0 %(22)

u/n = 4.0 %(1)

y = 25.0 %(3)

n = 66.7 %(8)

u/n = 8.3 %(1)

y = 32.1 %(9)

n = 57.1 %(16)

u/n = 10.7 %(3)

y = 31.6 %(6)

n = 68.4 %(13)

Information regarding VTE prophylaxis given to patient, % (number)

y = 28.0 %(7)

n = 56.0 %(14)

u/n = 16.0 %(4)

y = 50.0 %(6)

n = 41.7 %(5)

u/n = 8.3 %(1)

y = 35.7 %(10)

n = 28.6 %(8)

u/n = 35.7 %(10)

y = 57.9 %(11)

n = 21.1 %(4)

u/n = 21.1 %(4)

Total patients prescribed pharmacological VTE prophylaxis, % (number)

Y = 32(8)

N = 68(17)

y = 33.3(4)

n = 58.3(7)

u/n = 8.3(1)

y = 60.7(17)

n = 35.7(10)

u/n = 3.6(1)

y = 63.2(12)

n = 36.8(7)

Patients prescribed pharmacological VTE prophylaxis, where indication(s) present and contraindication(s) absent, % (number)

Y = 35.7 %(5)

N = 64.3 %(9)

(total = 14)

y = 100 %(4)

u/n = 20 %(1)

(total 5)

y = 81 %(17)

n = 19 %(4)

(total 21)

y = 81.8 %(9)

n = 18.2 %(2)

(total 11)

Patients prescribed pharmacological prophylaxis where contraindication(s) present, % (number)

Y = 25.0(2)

N = 75(6)

(Total =8)

n = 100(5)

(total 5)

n = 100(5)

(total 5)

y = 37.5(3)

n = 62.5(5)

(total 8)

Adherence to prescribed pharmacological VTE prophylaxis, % (number)

y = 32(8)

u/n = 68(17)

y = 25.0(3)

n = 8.3(1)

u/n and n/a = 66.6(8)

y = 57.1(16)

n = 3.6(1)

u/n = 39.3(11)

y = 63.2(12)

n/a = 36.8(7)

Correct dose of pharmacological VTE prophylaxis prescribed, % (number)

Y = 20(5)

N = 12(3)

n/a = 68(17)

y = 33.3(4)

n = 66.7(8)

y = 60.7(17)

n/a = 39.3(11)

y = 63.2(12)

n = 36.8(7)

How soon after admission pharmacological VTE prophylaxis prescribed, % (number)

<24 h = 16(4)

>24 h = 16(4)

n/a = 68(17)

<24 h = 33.3(4)

u/n and n/a = 66.6(8)

<24 h = 57.1(16)

>24 h = 3.6(1)

n/a = 39.3(28)

<24 h = 47.4(9)

>24 h = 15.8(3)

n/a = 36.8(7)

Type of pharmacological VTE prophlyaxis prescribed, % (number)

Enoxaparin = 32 (8)

Unfract.Hep

u/n = 68(17)

Enoxaparin = 33.3 (4)

None/na = 66.7(8)

Enoxaparin =60.7(17)

Unfract Hep 3.6 (1)

n/a = 35.7(10)

Enoxaparin = 63.2(12)

None/na = 36.8(7)

  1. This table shows prescribing-related data for patients prior to and following interventions within the urology department. The rows relate to the prescribing of pharmacological thromboprophylaxis, including indication, dose and timing and whether anti-coagulation was indicated or contra-indicated. The three rows highlighted in bold text relate to: 1. The documentation of an assessment of risk, 2. The provision of information to patients and 3. Whether a patient was appropriately prescribed anti-coagulation when indicated and not contra-indicated. These highlighted rows represent key measures of compliance related to NICE guidelines. The third highlighted row relates to the proportion of appropriate pharmacological thromboprophylaxis prescribing where there is an indication and an absence of known contraindications and is calculated from the prescribing data captured in the rows above
  2. Key: y yes, n no, u/n unknown
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us